Delving into the Latest Updates on Jiangsu Yayao Biotech Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

MDM2(p53-binding protein Mdm-2)	1

主要目的:评估口服 YY2201在晚期实体瘤患者中的安全性和耐受性;评估口服 YY2201在晚期实体瘤患者中的最大耐受剂量(MTD)和/或Ⅱ期推荐剂量(RP2D); 次要目的:评估 YY2201在晚期实体瘤患者中的药代动力学(PK)特征;初步评估口服 YY2201在晚期实体瘤患者中的抗肿瘤疗效。

[Translation]

Primary objectives: To evaluate the safety and tolerability of oral YY2201 in patients with advanced solid tumors; To evaluate the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of oral YY2201 in patients with advanced solid tumors; Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of YY2201 in patients with advanced solid tumors; To preliminarily evaluate the anti-tumor efficacy of oral YY2201 in patients with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Jiangsu Yayao Biotech Co., Ltd.

100 Clinical Results associated with Jiangsu Yayao Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Yayao Biotech Co., Ltd.

Login to view more data

100 Deals associated with Jiangsu Yayao Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Yayao Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Approval

Login to view more data